Bioorg Med Chem Lett 2016, 26, 3594-7.
The “gatekeeper” residue influences the mode of binding of acetyl indoles to bromodomains
J Med Chem 2016, 59, 3087-97.
Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation
Eur J Med Chem 2016, 112, 347-366.
Rational design of coumarin derivatives as CK2 inhibitors by improving the interaction with the hinge region
Mol Inf 2016, 35, 15-18.
Identification and regulation of the catalytic promiscuity of (−)-γ-lactamase from Microbacterium hydrocarbonoxydans
Appl Microbiol Biotechnol 2015, 99, 7559-68.
Current kinase inhibitors cover a tiny fraction of fragment space
Bioorg Med Chem Lett 2015, 25, 2372-76.
Structural analysis of the binding of type I, I1/2, and II inhibitors to Eph tyrosine kinases
ACS Med Chem Lett 2015, 6, 79-83.
Molecular dynamics in drug design
Eur J Med Chem 2015, 91, 4-14.
Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation
J Med Chem 2014, 57, 6834-44.
Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking
Bioorg Med Chem Lett 2014, 24, 2493-96.
Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk
Bioorg Med Chem Lett 2014, 24, 1523-27.
Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of the kinase domain generated by molecular dynamics
Bioorg Med Chem Lett 2013, 23, 5721-26.
Discovery of a novel chemotype of tyrosine kinase inhibitors by fragment-based docking and molecular dynamics simulations
ACS Med Chem Lett 2012, 3, 834-8.
Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics
ChemMedChem 2012, 7, 1983-90.
Hydrogen bonding penalty upon ligand binding
PLoS One 2011, 6, e19923.